Chronic oral anticoagulation and contemporary outcomes of elective endovascular aortic aneurysm repair
Hellenic Journal of Vascular and Endovascular Surgery · 2023
DOI: 10.59037/akkqth98 ↗Kurz gefasst
Fachartikel in der Zeitschrift Hellenic Journal of Vascular and Endovascular Surgery, 2023. Verfasst von Lara Dias und 3 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction and Objective Impact of chronic anticoagulation on endoleak risk after EVAR has been conflicting. Our aim was to assess how anticoagulation at time of EVAR can impact endoleak risk after EVAR.
Methods
A retrospective review of all patients submitted to elective EVAR for infra-renal abdominal aortic aneurysms from January 2018 to December 2021 was performed. Patients with isolated iliac aneurysms, complex repair (F/BEVAR) or presenting with rupture or symptomatic aneurysms were excluded. Patient demographics, procedural and post-operative outcomes were reviewed. Outcomes were defined according the SVS Reporting standards for endovascular aortic aneurysm repair. Primary endpoint was the impact of chronic anticoagulation type II EL after EVAR. Post-operative complications and reinterventions were also addressed. Survival analysis was preferred to compare endoleak occurrence among groups. Cox regression was performed to evaluated independent anticoagulation effect on type II EL occurrence.
Results
A total of 99 patients were identified, with 19 (19.2%) of these on chronic oral anticoagulation at time of EVAR. All anticoagulated patients were male and were older than non-anticoagulated patients (mean age 76.4 ±8.5 vs 71.4 ± 7.9, p=0.017). Patients on oral anticoagulation were more likely to have cardiac arrythmia, with no other differences regarding baseline comorbidities. There were no differences in type of anaesthesia or intra-operative complications. Four patients on anticoagulation were submitted to an additional procedure in the first 30-day (21.1% vs 7.5%, p=0.096). Mean follow-up was 18,9 ± 15,25 months. During follow-up, a total of 10 patients developed type II endoleak (EL): four patients in the anticoagulation group (21,1%), vs 6 non-anticoagulated patients (7,5%), p=0.032). After adjustment for age and gender, anticoagulated patients were at greater risk for type II EL (HR: 8.92, CI95% 1.65-48.12, p=0,011). Three-year overall survival was worst for anticoagulated patients, 49,1% vs 87,7%, p=
Zitieren
APA
Dias, L., Nóbrega, L., Oliveira-Pinto, J., & Mansilha, A. (2023). Chronic oral anticoagulation and contemporary outcomes of elective endovascular aortic aneurysm repair. Hellenic Journal of Vascular and Endovascular Surgery. https://doi.org/10.59037/akkqth98
Vancouver
Dias L, Nóbrega L, Oliveira-Pinto J, Mansilha A. Chronic oral anticoagulation and contemporary outcomes of elective endovascular aortic aneurysm repair. Hellenic Journal of Vascular and Endovascular Surgery. 2023. doi:10.59037/akkqth98
BibTeX
@article{Dias2023,
author = {Dias, Lara and Nóbrega, Leandro and Oliveira-Pinto, José and Mansilha, Armando},
title = {Chronic oral anticoagulation and contemporary outcomes of elective endovascular aortic aneurysm repair},
journal = {Hellenic Journal of Vascular and Endovascular Surgery},
year = {2023},
doi = {10.59037/akkqth98}
}
EUVIMED